Concord Biotech Ltd. Latest Updates

Recent Regulatory and Operational Highlights Concord Biotech successfully completed an inspection by the NAFDAC (National Agency for Food and Drug Administration and Control) at its Oral Solid Dosage Unit-2 facility located in Valthera, as announced in early October 2025. This successful completion is a positive indicator for its manufacturing compliance. Additionally, the company's Dholka API unit also cleared a Russian GMP inspection earlier, further expanding its regulatory footprint for Active Pharmaceutical Ingredients. 📈 Financial Performance Updates The company has released its unaudited standalone and consolidated financial results for the First Quarter (Q1) of the Fiscal Year 2025-2026 (period ended June 30, 2025). The consolidated revenue for Q1 FY26 stood at approximately ₹217.67 crores, and the Profit After Tax (PAT) was approximately ₹44.06 crores. The company reported a decline in revenue and net profit on both a quarter-on-quarter and year-on-year basis for this quarter. 💼 Strategy and Future Outlook The company continues to pursue growth through strategic focus areas. Its management has reiterated its commitment to launching 8-10 new products over the next three to four years, primarily in the oncology, anti-infectives, and anti-fungals segments. Concord Biotech is also actively exploring Contract Development and Manufacturing Organization (CDMO/CMO) opportunities globally and is optimistic about the future growth trajectory, supported by its upcoming injectable facility.